Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.

The humoral immune response requires antigen-specific B cell activation and subsequent terminal differentiation into plasma cells. Engagement of B cell antigen receptor (BCR) on mature B cells activates an intracellular signaling cascade, including calcium mobilization, which leads to cell proliferation and differentiation. Coengagement by immune complex of BCR with the inhibitory Fc receptor FcgammaRIIb, the only IgG receptor expressed on B cells, inhibits B cell activation signals through a negative feedback loop. We now describe antibodies that mimic the inhibitory effects of immune complex by high-affinity coengagement of FcgammaRIIb and the BCR coreceptor complex on human B cells. We engineered the Fc domain of an anti-CD19 antibody to generate variants with up to approximately 430-fold greater affinity to FcgammaRIIb. Relative to native IgG1, the FcgammaRIIb binding-enhanced (IIbE) variants strongly inhibited BCR-induced calcium mobilization and viability in primary human B cells. Inhibitory effects involved phosphorylation of SH2-containing inositol polyphosphate 5-phosphatase (SHIP), which is known to be involved in FcgammaRIIb-induced negative feedback of B cell activation by immune complex. Coengagement of BCR and FcgammaRIIb by IIbE variants also overcame the anti-apoptotic effects of BCR activation. The use of a single antibody to suppress B cell functions by coengagement of BCR and FcgammaRIIb may represent a novel approach in the treatment of B cell-mediated autoimmune diseases.

[1]  M. Iino,et al.  Inhibitory Modulation of B Cell Receptor-mediated Ca2+ Mobilization by Src Homology 2 Domain-containing Inositol 5′-Phosphatase (SHIP)* , 1999, The Journal of Biological Chemistry.

[2]  B. Heyman,et al.  IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. , 1999, Journal of immunology.

[3]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[4]  B. Diamond,et al.  Selective dysregulation of the FcγIIB receptor on memory B cells in SLE , 2006, The Journal of Experimental Medicine.

[5]  I. Mellman,et al.  Cutting Edge: FcγRII-B1 Regulates the Presentation of B Cell Receptor-Bound Antigens , 1998, The Journal of Immunology.

[6]  R. Tisch,et al.  Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice , 2007, Proceedings of the National Academy of Sciences.

[7]  G. Cooper,et al.  A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. , 2003, Arthritis and rheumatism.

[8]  M. Blank,et al.  The Role of Activating Protein 1 in the Transcriptional Regulation of the Human FCGR2B Promoter Mediated by the -343 G → C Polymorphism Associated with Systemic Lupus Erythematosus* , 2007, Journal of Biological Chemistry.

[9]  T. Yoshino,et al.  Deletion of Fcγ Receptor IIB Renders H-2b Mice Susceptible to Collagen-induced Arthritis , 1999, The Journal of experimental medicine.

[10]  P. Tempst,et al.  Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FeγRIIB , 1996, Nature.

[11]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[12]  J. Desjarlais,et al.  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[13]  D. Fearon,et al.  Activation of B lymphocytes: integrating signals from CD19, CD22 and FcγRIIb1 , 1996 .

[14]  A. Saxon,et al.  Modifications to an Fcγ-Fcɛ fusion protein alter its effectiveness in the inhibition of FcɛRI-mediated functions , 2007 .

[15]  Kenneth G. C. Smith,et al.  Distinct cell-specific control of autoimmunity and infection by FcγRIIb , 2008, The Journal of experimental medicine.

[16]  W. Fridman,et al.  Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. , 1992, Science.

[17]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[18]  A. Lanzavecchia,et al.  Mechanisms of antigen uptake for presentation. , 1996, Current opinion in immunology.

[19]  T. McGaha,et al.  Restoration of Tolerance in Lupus by Targeted Inhibitory Receptor Expression , 2005, Science.

[20]  B. Heyman,et al.  Feedback regulation by IgG antibodies. , 2003, Immunology letters.

[21]  A. Saxon,et al.  A mouse Fcγ-Fcε protein that inhibits mast cells through activation of FcγRIIB, SH2 domain–containing inositol phosphatase 1, and SH2 domain–containing protein tyrosine phosphatases , 2008 .

[22]  Yi Liu,et al.  Inhibitory Fc Gamma Receptors: From Gene to Disease , 2004, Journal of Clinical Immunology.

[23]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Cozzarelli,et al.  References and Notes Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Sequence-directed Dna Translocation by Purified Ftsk , 2022 .

[25]  V. Duronio,et al.  Two Distinct Waves of Membrane-Proximal B Cell Antigen Receptor Signaling Differentially Regulated by Src Homology 2-Containing Inositol Polyphosphate 5-Phosphatase 1 , 2004, The Journal of Immunology.

[26]  P. Kiener,et al.  Co-ligation of the Antigen and Fc Receptors Gives Rise to the Selective Modulation of Intracellular Signaling in B Cells , 1997, The Journal of Biological Chemistry.

[27]  S. Bolland,et al.  FcγRIIB as a modulator of autoimmune disease susceptibility , 2007 .

[28]  R. Kimberly,et al.  Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. , 2006, Arthritis and rheumatism.

[29]  R. Kimberly,et al.  Expression Profile of FcγRIIb on Leukocytes and Its Dysregulation in Systemic Lupus Erythematosus1 , 2007, The Journal of Immunology.

[30]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[31]  A. Basten,et al.  Reduced life span of anergic self-reactive B cells in a double- transgenic model , 1994, The Journal of experimental medicine.

[32]  Emi Masuda,et al.  Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus , 2005, Human Genetics.

[33]  A. Snow,et al.  CD 72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes 1 , 2006 .

[34]  Hyo Jeong Hong,et al.  Antibody engineering for the development of therapeutic antibodies. , 2005, Molecules and cells.

[35]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[36]  E. Voss,et al.  Comparison of variable region primary structures within an anti-fluorescein idiotype family. , 1989, The Journal of biological chemistry.

[37]  M. Nussenzweig,et al.  A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling , 1994, Nature.

[38]  J. V. D. van de Winkel,et al.  Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. , 1994, Journal of immunology.

[39]  R. Warnke,et al.  A unique human B lymphocyte antigen defined by a monoclonal antibody. , 1984, Hybridoma.

[40]  Kenneth G. C. Smith,et al.  B cell inhibitory receptors and autoimmunity , 2003, Immunology.

[41]  J. Cambier,et al.  Effects of Src Homology Domain 2 (SH2)-Containing Inositol Phosphatase (SHIP), SH2-Containing Phosphotyrosine Phosphatase (SHP)-1, and SHP-2 SH2 Decoy Proteins on FcγRIIB1-Effector Interactions and Inhibitory Functions1 , 2000, The Journal of Immunology.

[42]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[43]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[44]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[45]  P. Umaña,et al.  The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. , 2006, The Journal of biological chemistry.

[46]  Janet M. Allen,et al.  Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts , 2005, Nature Medicine.

[47]  S. Pierce,et al.  Regulation of B cell receptor-mediated MHC class II antigen processing by FcgammaRIIB1. , 1999, Journal of immunology.

[48]  N. Sinclair,et al.  Regulation of the immune response. VI. Inability of F(ab') 2 antibody to terminate established immune responses and its ability to interfere with IgG antibody-mediated immunosuppression. , 1973, Immunology.

[49]  M. Ono,et al.  Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. , 2000, The Journal of experimental medicine.

[50]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[51]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[52]  T. Kelley,et al.  Role of SHIP in FcgammaRIIb-mediated inhibition of Ras activation in B cells. , 1998, Molecular immunology.

[53]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[54]  A. Snow,et al.  CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes1 , 2006, The Journal of Immunology.

[55]  J. Ravetch,et al.  The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells , 2005, Nature Immunology.

[56]  J. Ravetch,et al.  The antiinflammatory activity of IgG: the intravenous IgG paradox , 2007, The Journal of experimental medicine.

[57]  Herren Wu,et al.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.

[58]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[59]  T. Tedder,et al.  CD19 Amplification of B Lymphocyte Ca2+ Responses , 2001, The Journal of Biological Chemistry.

[60]  J. Cambier,et al.  Partially Distinct Molecular Mechanisms Mediate Inhibitory FcγRIIB Signaling in Resting and Activated B Cells1 , 2001, The Journal of Immunology.

[61]  A. DeFranco,et al.  The complexity of signaling pathways activated by the BCR. , 1997, Current opinion in immunology.

[62]  M. Harnett,et al.  Dissection of the signalling mechanisms underlying FcgammaRIIB-mediated apoptosis of mature B-cells. , 2004, Biochemical Society transactions.

[63]  S. Pierce.  Lipid rafts and B-cell activation , 2002, Nature Reviews Immunology.

[64]  M. Ono,et al.  Fc g Receptor IIB–deficient Mice Develop Goodpasture’s Syndrome upon Immunization with Type IV Collagen: A Novel Murine Model for Autoimmune Glomerular Basement Membrane Disease , 2000 .